Takeda receives clearance from the State Administration for Market Regulation in China for the proposed acquisition of Shire plc
Osaka, Japan, September 14, 2018 — Takeda Pharmaceutical Company Limited (“Takeda”) announces that it has received unconditional clearance from the State Administration for Market Regulation in China (“SAMR”) for the proposed acquisition of Shire plc announced on May 8, 2018 (the “Acquisition”).
As announced on July 10, 2018, Takeda has received unconditional clearance for the Acquisition from the United States Federal Trade Commission.
As confirmed on August 28, 2018, Takeda has received unconditional clearance from the Brazilian Administrative Council for Economic Defense.
SAMR’s unconditional clearance of the Acquisition is another key step in the transaction process.